Study: Ability of Kre-Alkalyn® to Eliminate Joint Inflammation and Pain

Formula For Success: All American Pharmaceutical Gearing Up For Expansion
December 1, 2014
Another First For All American Pharmaceutical
December 16, 2014
Show all

Study: Ability of Kre-Alkalyn® to Eliminate Joint Inflammation and Pain

Kre-Alkalyn® & Its Ability to Eliminate Workout-Related Joint Inflammation and Pain in Football Players

Jeff Golini, PhD.
All American Pharmaceutical, Billings Montana

Background

Sports-related joint and tissue inflammation becomes chronic in professional football players due to the nature of this high-impact and physically punishing sport. These athletes — many of whom weigh in excess of 250 to 300 pounds, can expect to begin experiencing the effects of excessive joint/ligament overuse early in their career. Joint stiffness often precipitates additional injuries as the athlete pushes himself in long workouts, further overextending inflamed tissue in an attempt to compensate and improve performance. Over time, this repeated inflammation leads to permanent damage, eventually ending a football player’s career.

For more than 25 years, creatine has been used by athletes who are engaged in high-energy sports. But until recently, the ability of creatine to influence cell surface interactions has been largely ignored. In cell culture studies, creatine monohydrate has demonstrated the capability of modulation certain aspects of cell surface/pro-inflammatory reactant interactions.

Study Objective

To determine whether a unique, oral alkali buffered-creatine monohydrate compound is capable of reducing, or eliminating, workout-related joint and tissue inflammation and pain.

Participants and Method

A total of 30 male professional football players were selected to participate. Individuals ranged in weight from 185 lbs to 380 lbs, and all experienced at least one area of chronic, pre-workout related joint-tissue and stiffness. Eighteen athletes were assigned to take the Test Material (Kre-Alkalyn®); 12 were given a placebo (Maltodextrin).

Volunteers were divided into three groups: Group A (n = 12) received 1500 mg of Kre-Alkalyn® in the morning, daily (a total of 2 capsules) for six weeks; Group B (n = 6) received 1500 mg of Kre-Alkalyn® in the morning, daily for the first 7 days, then 3000 mg daily (1500 mg AM / 1500 mg PM) for five additional weeks; Groups C (n = 12) received two placebo capsules daily for six weeks. In addition, participants were required to report all incidences of joint pain and or stiffness on a daily basis to their coordinator, according to protocol.

Results

All initially reported joint pain/stiffness disappeared before the conclusion of the six week study.

Summary

Our findings indicate that Kre-Alkalyn® was effective in eliminating pain and stiffness in the football players. In addition, it was noted that there was a general trend toward increasing endurance and stamina, eliminating fatigue and decreasing total body fat by between 1% – 3.5% overall.

Research Poster Presentation Image:

Dr. Jeff Golini
Dr. Jeff Golini
Dr. Jeff Golini is the Founder, CEO and Executive Scientist of All American Pharmaceutical. He holds numerous patents for innovative compounds such as, Kre-Alkalyn buffered creatine monohydrate, Karbolyn, the high-performance carbohydrate, and Kre-Celazine.

Comments are closed.